The latest price target for Century Therapeutics (NASDAQ:IPSC) was reported by Chardan Capital on November 7, 2024. The analyst firm set a price target for $11.00 expecting IPSC to rise to within 12 months (a possible 890.99% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Century Therapeutics (NASDAQ:IPSC) was provided by Chardan Capital, and Century Therapeutics maintained their buy rating.

There is no last upgrade for Century Therapeutics

The last downgrade for Century Therapeutics Inc happened on August 28, 2023 when JP Morgan changed their price target from $28 to $5 for Century Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Century Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Century Therapeutics was filed on November 7, 2024 so you should expect the next rating to be made available sometime around November 7, 2025.

While ratings are subjective and will change, the latest Century Therapeutics (IPSC) rating was a maintained with a price target of $17.00 to $11.00. The current price Century Therapeutics (IPSC) is trading at is $1.11, which is out of the analyst’s predicted range.